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Abstract 
Regulation of gene expression at the level of transcriptional elongation has 
been shown to be important in stem cells and tumour cells, but its role in the 
whole animal is only now being fully explored. Neural crest cells (NCCs) are a 
multipotent population of cells that migrate during early development from the 
dorsal neural tube throughout the embryo where they differentiate into a variety 
of cell types including pigment cells, cranio-facial skeleton and sensory neurons. 
Specification of NCCs is both spatially and temporally regulated during 
embryonic development. Here we show that components of the transcriptional 
elongation regulatory machinery, CDK9 and CYCLINT1 of the P-TEFb complex, 
are required to regulate neural crest specification. In particular, we show that 
expression of the proto-oncogene c-Myc and c-Myc responsive genes are 
affected. Our data suggest that P-TEFb is crucial to drive expression of c-Myc, 
which acts as a ‘gate-keeper’ for the correct temporal and spatial development 
of the neural crest. 
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Introduction 
 
RNA polymerase pausing and transcriptional elongation is important in 
the specification of many types of cells including embryonic stem (ES) cells. In 
order for genes to undergo transcription, RNA polymerase II (Pol II) must be 
recruited to the promoter region (Hochheimer and Tjian, 2003). Subsequent to 
this, RNA Pol II may undergo regulation to temporally control the expression of 
genes in specific cell types. Such regulation includes the promoter proximal 
pausing of Pol II, the process by which Pol II undergoes stalling or poising at 
the 5’ end of a gene just downstream of the transcription start site (Core and 
Lis, 2008). This occurs due to binding of pause factors, DRB-sensitivity 
inducing factor (DSIF), negative elongation factor (NELF) and Gdown1 (Cheng 
et al., 2012; Wada et al., 1998; Yamaguchi et al., 1999). In order for 
transcriptional elongation to commence the positive transcription elongation 
factor (P-TEFb) must be recruited to the transcription elongation complex. P-
TEFb is known to be a complex composed of cyclin dependent kinase 9 (CDK9) 
and cyclin T1 (Bres et al., 2008; Fujita et al., 2009; Jonkers and Lis, 2015; 
Kohoutek, 2009). To initiate transcriptional elongation, P-TEFb phosphorylates 
serine2 of the c-terminal domain (CTD) of Pol II and the SPT5 subunit of DSIF. 
After this phosphorylation, NELF dissociates from the complex and 
transcriptional elongation begins (Fujita et al., 2009). This process occurs when 
P-TEFb is in its active form and part of a collective of several proteins, termed 
the super elongation complex (SEC), which is known to regulate transcriptional 
elongation (Luo et al., 2012a; Zhou et al., 2012). 
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 The SEC is recruited to the promoter region of genes when rapid 
transcription is required in response to specific developmental signals, changes 
to available nutrition or even acute temperature change. It is because of this 
that the genes primarily regulated by RNA polymerase pausing are master 
regulator genes and/or rapid response genes such as heat shock and serum 
inducible genes (Fuda et al., 2009; Luo et al., 2012b). It has also been 
suggested that the main function of SEC recruitment to paused genes is not 
necessarily to allow rapid induction but also to synchronise genes in 
development (Boettiger and Levine, 2009). Work in Drosophila and ES cells 
has shown that transcription elongation is not important globally within the 
genome but is found to regulate 10-40% of genes. Some of these genes have 
been identified as crucial developmental control genes (Gaertner and Zeitlinger, 
2014; Zeitlinger et al., 2007).  
 The neural crest is a transient embryonic cell population found 
exclusively in vertebrates. Neural crest cells (NCCs) migrate from the dorsal 
neural tube to various parts of the embryo where they differentiate to give rise 
to a diverse set of cell types (Milet and Monsoro-Burq, 2012; Pegoraro and 
Monsoro-Burq, 2013; Sauka-Spengler and Bronner-Fraser, 2008). These 
include enteric ganglia, neuroendocrine cells, melanophores, and craniofacial 
skeletal and connective tissue, thus NCCs are multi-potent progenitors. Their 
induction and specification begins during the early gastrula stage of 
development and continues throughout organogenesis. This process depends 
on multi-module gene regulatory networks acting between the neural plate, 
non-neural ectoderm and paraxial mesoderm (Buitrago-Delgado et al., 2015; 
Hoppler and Wheeler, 2015; Huang and Saint-Jeannet, 2004; Sauka-Spengler 
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and Bronner-Fraser, 2008). Multiple signals and transcription factors are 
responsible for neural crest (NC) properties such as multipotency, induction, 
specification, migration and differentiation (Sauka-Spengler and Bronner-
Fraser, 2008). 
Once the neural plate border is fully specified and NCCs have been 
induced, neural crest specifiers begin to act (Milet and Monsoro-Burq, 2012). 
These include the transcription factors Snail1, Snail2 (Slug), Sox8, Sox9, 
Sox10, FoxD3, and c-Myc. After specification morphological changes in the 
neural crest cells including changes to shape, adhesion and cell motility enable 
the cells to migrate from the dorsal neural tube (Sauka-Spengler and Bronner-
Fraser, 2008). Neural crest specifiers can be separated into two groups; early 
and late NC specifiers. Expression of early neural crest specifiers, including c-
Myc, and Snail1, is first identified at the neural plate border, whilst expression 
of slightly later neural crest specifiers such as Snail2 and FoxD3 is seen in pre-
migrating neural crest and can continue throughout migration. Only after these 
have all started to be expressed does expression of members of the SoxE 
family such as Sox10 start (Sauka-Spengler et al., 2007). It has been suggested 
that the early neural crest specifier c-Myc may have a role in maintaining neural 
crest cell multipotency and proliferation by maintaining a balance between cell 
death and proliferation following NC specification (Bellmeyer et al., 2003; Kee 
and Bronner-Fraser, 2005; Light et al., 2005). 
 Using chemical genetic screens we have previously identified small 
molecules that affect pigment cell development (Tomlinson et al., 2005; 
Tomlinson et al., 2009a; Tomlinson et al., 2009b). One of these, the small 
molecule leflunomide, inhibits pigment cell development in Xenopus and 
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Zebrafish (Elworthy et al., 2003; Tomlinson et al., 2009b; White et al., 2011). In 
addition, leflunomide inhibits melanoma tumour growth in tissue culture and in 
mouse xenografts. Leflunomide inhibits the enzyme dihydro-orotate 
dehydrogenase, a rate limiting enzyme in the pyrimidine biosynthesis pathway. 
It acts to inhibit transcriptional elongation of genes required for neural crest 
development and melanoma growth by limiting the pool of pyrimidines in the 
cell (White et al., 2011).  
 Here we further investigate leflunomide’s ability to inhibit transcriptional 
elongation during neural crest development and show that it prevents 
expression of both, early and late neural crest specifiers such as Snail2, Sox10 
and FoxD3 and c-Myc. As leflunomide acts through inhibiting transcriptional 
elongation we speculated that regulation of transcriptional elongation could be 
crucial for neural crest development. We therefore characterised the temporal 
and spatial expression of components of the Positive Transcription Elongation 
Factor B (P-TEFb) complex, Cdk9 and CyclinT1, during neural crest 
development in X. laevis. CDK9 and CYCLINT1 loss-of-function analyses by 
morpholino knockdown closely mimic the phenotypes induced by leflunomide 
treatment. Interestingly, we identify c-Myc as a gene susceptible to regulation 
of transcriptional elongation in the early NC and show that it is able to rescue 
CDK9 and CYCLINT1 morphant phenotypes. This is backed up by ChIP 
sequencing data of Xenopus embryos which shows the c-Myc gene to be one 
of the most ‘paused’ genes in the genome. We thus propose regulation at the 
level of transcriptional elongation to be important in NC development through 
the driving of c-Myc expression.  
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Results 
The expression of the P-TEFb complex components during Xenopus laevis 
development 
 We have previously shown that inhibition of transcriptional elongation 
leads to defects in neural crest development (White et al. 2011). An important 
regulator of transcriptional elongation is the P-TEFb complex. We therefore 
decided to investigate the role of the components of the P-TEFb complex during 
Xenopus development. The P-TEFb complex is comprised of CDK9 and 
CYCLINT1. Expression analysis showed Cdk9.S, Cdk9.L and CyclinT1 to be 
expressed in the neural plate and neural plate border of neurula stage embryos 
(Fig. 1). In tailbud stage embryos at stages 26 and 32 expression was seen in 
the NC derived branchial arches. To determine if their expression overlapped 
with the NC, we carried out double in situ hybridisations at st16 for all three P-
TEFb components with the neural crest marker Sox10. Expression of the 
Cdk9.S, Cdk9.L and CyclinT1 overlapped with expression of Sox10, indicating 
that the P-TEFb complex is expressed in neural crest cells (Fig. 1).  
 
Leflunomide treatment affects the development of neural crest derivatives  
Leflunomide was identified as an inhibitor of NC as a result of chemical 
screens carried out with the aim to look for small molecules that affect pigment 
cell development. Our previous results concentrated on the effects of 
leflunomide on zebrafish neural crest (White et al., 2011). Here we look at the 
effects of leflunomide in more detail on Xenopus neural crest. Leflunomide 
inhibits the formation of Xenopus laevis melanophores in a dose dependent 
manner and causes a loss of melanophores when added to the embryo after 
Transcriptional elongation and Neural Crest 9 
gastrulation (Fig. 2A and B). Initially, a leflunomide dose response was used 
to establish the general phenotype induced by the compound. DMSO treated 
embryos served as a control. Embryos were treated at a range of 
concentrations from stage 15 and analysed at stage 38 (Fig. 2Ai). Leflunomide 
treatment led to a loss of melanocytes in the underside of the tail, head and 
lateral stripe of the embryo (Fig. 2Ai black arrow heads). This phenotype was 
dose dependant, with 60 μM leflunomide demonstrating the most severe 
phenotypes occurring in a significant number of embryos (Fig. 2Bi). Treating 
Xenopus embryos at earlier stages showed a stronger effect on pigment cell 
development along with a shortened axis  (Fig. 2Aii and Bii). 
 
Leflunomide inhibits transcription of neural crest specifier genes.  
 Next, we looked at how leflunomide treatment affects the expression of 
genes known to play a role at different stages of neural crest development. 
Embryos were treated with 60 μM leflunomide or DMSO from fertilisation and 
examined by in situ hybridisation for different markers of neural crest 
development (Fig. 2C and D). The expression of the neural plate border 
markers Zic1, Zic3 and Pax3 did not change after leflunomide treatment when 
compared to the DMSO control (Fig. 2C). This suggests that leflunomide does 
not interfere with these early stages of neural crest development.  There was 
also no significant change seen in Sox2 expression throughout the neural plate 
(Fig. 2C) suggesting that neural development is largely unaffected by 
leflunomide treatment. We next tested genes known to play a role in neural 
crest specification. The earliest neural crest specifier gene, which showed a 
loss in expression was c-Myc. This gene gave an interesting expression pattern 
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as it appeared that leflunomide-mediated inhibition of c-Myc expression was 
restricted to the areas fated to become neural crest (Fig. 2D black arrows). 
Loss of c-Myc expression was not observed in more posterior neural domains. 
Later neural crest specifiers, such as Sox10, were also significantly reduced 
after leflunomide treatment (Fig. 2D black arrows) and also shown to be only 
affected in the NC as expression in the otic vesicle (ear) was not affected (Fig. 
S8). In addition we examined the neural crest specifiers Slug/Snail2 and FoxD3 
(Fig. 2D). Many embryos showed a partial loss or an alteration in the 
expression of these genes. Quantification of these results (Fig. S1 A) showed 
that c-Myc and Sox10 show the strongest loss of expression. These results 
were confirmed by qRT-PCR on whole embryos (Fig. S1 B). Using this 
technique we found that neural plate border markers Zic1, Zic3, Pax3 and the 
neural plate marker Sox2 displayed no significant change in expression level 
(Fig. S1 B). Similarly to the in situ hybridisation data we saw a significant 
decrease in expression of neural crest specifying genes c-Myc, Sox10, 
Slug/Snail2, and Sox9 (Fig. S1 B).  
 
RNA sequencing carried out on animal caps treated with leflunomide 
To characterise the tissue specific effects of leflunomide treatment we 
carried out RNA sequencing on animal cap explants induced to become neural 
crest, neuroectoderm or ectoderm. Animal caps were cut at stage 9 and 
immediately immersed into either 60 μM leflunomide or DMSO and allowed to 
develop until stage 15. The genes predominantly down-regulated in the neural 
crest animal cap sample were genes involved in neural crest specification and 
general development (Fig. 2E and Fig. S1 C). Most of these genes, were 
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previously identified to be affected by in situ hybridisation such as c-Myc, Sox10, 
FoxD3, Slug/Snail2 and Sox9. Interestingly Snail1 expression was not affected 
by leflunomide. In agreement with our in situ data, we saw no change in neural 
plate markers, such as Sox1 and Sox2, or neural plate border markers, such 
as Zic1, Zic3 and Pax3. Other categories of down regulated genes included 
genes involved in eye development and metabolism, both of which are closely 
associated with neural crest development. Interestingly we saw down-
regulation of heat shock genes (Hsp90aa1.1, Hsp105 and Hsp110), which were 
some of the first genes suggested to be controlled by RNA polymerase pausing 
and transcriptional elongation (Andrulis et al., 2000; Keegan et al., 2002; Lis et 
al., 2000). The neuroectoderm sample showed a decrease in the expression of 
genes, which restrict neuroectoderm fate e.g. Grainyhead-like 3, suggesting an 
increase in neuroectoderm cell fate. The ectoderm sample showed no 
significant increase or decrease in any other genes suggesting that regulation 
of transcriptional elongation is not important for ectoderm development. These 
results indicate that interference with transcriptional elongation in this system 
mostly affects neural crest development. We found expression of c-Myc to be 
slightly downregulated in the neural crest sample with no change seen in the 
neuroectodem sample and it only shows low expression in the ectoderm.  This 
result agrees with the in situ hybridisation results obtained (Fig. 2D). The small 
decrease in the NC sample is likely due to a masking of any decrease by 
contaminating neural tissue, which is always found in the NC animal caps. A 
full list of all genes affected in all three sample types can be found in 
Supplementary data 1. Overall, this data confirmed our findings that 
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leflunomide acts to inhibit NC development and that this could be due to 
inhibition of transcriptional elongation.  
  
Knockdown of the P-TEFb components leads to defects in neural crest 
development 
 To determine the requirement of the P-TEFb complex and subsequent 
transcriptional elongation for NCC development, we carried out knockdown 
studies of the individual components. We obtained morpholinos (MO) for 
CDK9.S, CDK9.L and CYCLINT1. Morpholino sequences and controls are 
shown in Fig. S2. CDK9 MOs were injected individually and in combination at 
the one or two cell stage. Embryos injected with these morpholinos were left to 
develop until stage 38. The phenotype obtained after knockdown of the P-TEFb 
components was comparable to that obtained after leflunomide treatment. The 
MO-injected embryos displayed neural crest defects including loss of pigment 
cells (Fig. 3A and Fig. S3A) comparable to those shown in Fig. 2 and 
disorganisation of cranial cartilage (Fig S3B). 
We next carried out in situ hybridisation using neural plate border genes, 
neural crest specifier genes and a neural plate marker. Embryos were injected 
with a standard control Morpholino, CDK9.S morpholino or the CYCLINT1 
morpholino along with 300 pg of LacZ cRNA into one cell of a two-cell stage, 
with the non-injected half serving as control (Fig. 3B Fig. S3D and Fig. S7). 
The expression of neural plate border markers Zic1, Zic3 and Pax3 were not 
affected (Fig. 3B). The Neural plate marker Sox2 and other neural genes were 
not affected (Fig 3B and S5). c-Myc and Sox10 however, showed a striking 
knockdown after CDK9.S-MO or CYCLINT1-MO (Fig. 3B). Loss of c-Myc was 
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seen specifically in the anterior patches, which give rise to NC (black arrows 
Fig. 3B). Complete loss of Sox10 expression was seen in the NC (black arrows 
Fig. 3B). These results were confirmed using qRT-PCR (Fig. S4C). The same 
experiment was carried out after injection of the CDK9.L MO, or a combination 
of the CDK9.S and CDK9.L MOs and this data is shown in Fig. S4A and B. 
When embryos were allowed to progress to stage 26 an effect on Sox10 
expression in the cranial NC can be seen but no change in expression of Sox10 
is seen in the otic vesicle (Fig. S8). In Leflunomide treated embryos Sox10 
expression in the otic vesicle is also not affected while there is a loss of 
expression in the cranial NC and pigment cells (Fig. S8). Other neural crest 
markers Slug/Snail2, FoxD3 and Sox9 show some alteration and partial loss of 
expression, but very little complete loss of expression (Fig. 3B and Fig. S4). In 
support of the RNA-Seq data expression of Snail1, which is also an early 
specifier of NC, was not affected by knockdown of P-TEFb components (Fig. 
S7). The phenotypes after P-TEFb knock-down were strikingly similar to those 
obtained after leflunomide treatment (Figs. 2C and D).  
c-Myc is also known to regulate the development of trigeminal placodes 
in the anterior region of the embryo. We therefore looked at the expression of 
placodal markers by WISH. The placode markers we used include Tbx2, 
NeuroD and ElrD, which are expressed in the trigeminal placodes and the 
neural tube (Green and Vetter, 2011; Schlosser and Ahrens, 2004; Showell et 
al., 2006). We were able to detect a loss of expression of all three markers, 
specifically in the trigeminal placode region, but not in any of the other tissues 
in which they are expressed (Fig. 3C and Fig. S4D).  
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c-Myc is a paused gene during development 
As c-Myc is the earliest gene to be affected by Leflunomide and the 
knockdown of the P-TEFb components, we looked at the RNA pol II occupancy 
profile of c-Myc and compared it to the promoter histone modification H3K4me3 
and the processive elongation mark H3K36me3. These data suggest that c-
Myc is in a paused or poised state during mid to late gastrula just before the 
NC are specified (Fig. 4A). We next carried out RNA Pol II ChIP-seq on 
embryos injected with CDK9.S morpholino compared to embryos injected with 
control morpholino. Knockdown of Cdk9 causes an increase in RNA Pol II 
occupance, the effect of which is the stongest on the promoter, suggesting that 
there is an increase in pausing of c-Myc (Fig 4A, blue tracks). We determined 
the pausing index values for all annotated genes and Fig 4Bi shows that there 
is an overall increase in pausing. This would be expected given that 
transcriptional elongation is effectively being suppressed. Fig 4Bii highlights 
that the loss of CDK9 causes an increase in the amount of RNA Pol II bound to 
the promoter compared to the rest of the gene body. The position of c-Myc is 
shown by the blue spot. While the RPKM on its gene body is increased from 5 
to 10, the RPKM on its TSS goes from 11 to 50. This suggests that c-Myc is 
particularly sensitive to control of expression at the level of transcriptional 
elongation and is therefore in a more ‘paused’ state. 
 
c-Myc is regulated by transcriptional elongation in neural crest cells  
We postulated that c-Myc could be the primary gene regulated by 
transcriptional elongation in neural crest cells. We therefore examined if loss of 
Sox10 expression after P-TEFb morpholino injection could be rescued by co-
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injecting c-Myc RNA. For this experiment CDK9.S morpholino and CYCLINT1 
morpholinos were injected alone or with 100 pg of c-Myc and 500pg of c-Myc 
RNA. As before, knockdown of CDK9.S and CYCLINT1 led to a high number 
of embryos displaying loss of Sox10 expression (Fig. 5A and B). Co-injection 
of these morpholinos with 100 pg of c-Myc resulted in a reduction of the number 
of embryos displaying a loss of expression phenotype. The majority of embryos 
displayed a partial loss phenotype or wild type phenotype. After injection of 500 
pg of c-Myc RNA a greater number of embryos displayed a wild type phenotype 
(Fig. 5A and B). Injection of 500 pg of c-Myc alone had very little effect on 
Sox10 expression and injection of the standard control MO did not affect Sox10 
expression (Fig. 5B). Injection of c-Myc RNA into one blastomere was also 
shown to rescue leflunomide treated embryos on the injected side (Fig S6). 
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Discussion 
 The molecular mechanisms controlling NCC specification and 
differentiation are complex and consist of many layers of regulation to ensure 
the cells decide upon the correct lineage and form the correct cell types. Other 
multipotent cell types such as embryonic stem cells and haematopoietic stem 
cells are thought to undergo regulation at the level of transcriptional elongation 
(Bai et al., 2010; Lin et al., 2011). It has previously been shown that Foggy 
mutant Zebrafish, which are deficient in the SPT5 subunit of DSIF, display 
pigmentation and cardiac defects suggesting a disruption in neural crest 
development (Keegan et al., 2002). In addition the Xenopus tropicalis mutant 
cyd vicious, which displays pigmentation defects, is also mutated in the Spt5 
gene (Lyle Zimmerman, personal communication). Here we provide evidence 
for direct regulation of the specification of NC at the level of transcriptional 
elongation by the P-TEFb complex. In addition, we show that in the NC, c-Myc 
is the crucial gene regulated at the level of transcriptional elongation.  
 The methods used in this study were firstly to use leflunomide as an 
inhibitor of transcriptional elongation and secondly, through the use of 
morpholino knockdowns of components of the P-TEFb complex to block 
transcriptional elongation. Both of these methods gave comparable results 
(Figs. 2 and 3, Figs S1-4). Both demonstrate a disruption in the development 
of neural crest derivatives including melanophores, sensory neurons and 
cranio-facial cartilage. When looking at the levels of expression of genes 
involved in the neural crest gene regulatory network the two genes 
demonstrating the greatest level of knockdown by WISH, qRT-PCR or RNAseq 
were c-Myc, an early NC specifier and Sox10, a NC specifier downstream of c-
Myc also expressed in the migrating NC. Furthermore, we showed that the loss 
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of Sox10 gene expression in the NC was rescued by injecting embryos with c-
Myc RNA (Fig. 5).  
To investigate whether c-Myc expression was directly regulated by the 
P-TEFb complex and transcriptional elongation, we looked at cell types other 
than neural crest cells, which are known to have c-Myc within their gene 
regulatory network. We reasoned that if c-Myc is a direct target a loss in 
expression of markers for these other cell types should be observed. Our in situ 
hybridisation data suggested that c-Myc expression in the placodal regions is 
lost after knockdown of P-TEFb components (Fig. 3B), as opposed to more 
posterior neural expression, which was not affected.  We therefore looked at 
the trigeminal placodes, which are similar to NC and which express c-Myc in 
the early stages of their gene regulatory network (Bellmeyer et al., 2003; 
Grocott et al., 2012). We were able to detect a loss of expression of three 
markers, specifically in the trigeminal placode region, but not in any of the other 
tissues in which they are expressed (Fig. 3C and Fig. S4D). This provides 
further evidence for c-Myc itself being directly regulated by transcriptional 
elongation in specific tissues. Interestingly we also see a loss of Rohon-Beard 
cell markers (Runx1, Islet1 and Ngnr1) upon knockdown of the P-TEFb 
complex (Fig S4E). It is currently not known whether c-Myc signalling is 
required for the development of these cells. The combination of the loss of 
neural crest cells, trigeminal placodes and Rohon-Beard cells causes embryos 
treated with leflunomide or CDK9 morpholino to become insensitive to touch 
response assays as shown in (Fig S3C and Supp movies 1-3). 
 Our ChIP-Seq analysis (Fig 4) shows c-Myc to be a paused gene during 
early development and that the inhibition of transcriptional elongation by Cdk9 
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morpholino causes c-Myc to become even more paused compared to the rest 
of the genome. This is consistent with studies using human 293T embryonic 
kidney cell lines, which have also shown c-Myc to be a paused gene (Takahashi 
et al., 2011). Rahl and colleagues (Rahl et al., 2010) have previously shown in 
tissue culture that c-MYC can directly regulate the activity of P-TEFb. This 
suggests the activation of c-Myc by signals such as WNT (Bellmeyer et al., 
2003) could lead to a positive feedback system where c-MYC activates P-TEFb 
which in turn promotes transcriptional elongation of the c-Myc gene. Our rescue 
experiments in Fig 5 and Fig S6 suggests c-Myc overexpression can overcome 
the effect of loss of P-TEFb activity. However we cannot exclude the possibility 
that the increased amount of c-MYC in these embryos may increase any 
residual P-TEFb activity to overcome the loss of activity from the MO. Either 
way it still underlines the crucial role for regulation at the level of transcriptional 
elongation and the role of c-Myc in this process. 
Our RNA-Seq results using animal cap explants show that when the 
three cell types NC, neuroectoderm and ectoderm have inhibited transcriptional 
elongation the only cell type to show specific changes was the NC. We show 
down regulation of c-Myc expression in the neural crest sample and observed 
little change in the neural and ectoderm samples (Supplementary data 1). This 
gives us further reason to suggest that regulation of c-Myc expression by 
transcriptional elongation is occurring only in specific tissues, in this case the 
NC.  
Overall, these results provide evidence that c-Myc is the ‘gate-keeper’ 
regulated by transcriptional elongation in both, the NC and trigeminal placodes, 
and that expression of the downstream marker Sox10 in the NC is lost as a 
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secondary effect of this. This is consistent with previous analysis of microarrays 
from melanoma tumours where many c-Myc responsive genes were affected 
by leflunomide treatment (White et al., 2011). Our results are summarised as a 
model in Fig. 6. We propose that the c-Myc gene is held in a paused state 
within NCCs and not in all tissues. This paused state is then specifically 
released in a wild type NC cell by the P-TEFb complex to allow normal c-Myc 
transcription and therefore promote synchronous transcription of downstream 
genes such as Sox10 and the subsequent differentiation of neural crest 
derivatives (Fig. 6 top route). MYC is known to actually stimulate recruitment of 
P-TEFb to promoters of active genes thus leading to increased expression in a 
process called transcriptional amplification (Rahl and Young, 2014). The results 
obtained from our P-TEFb knockdown studies and leflunomide treated embryos 
suggest that when the function of P-TEFb is impaired c-Myc is no longer 
expressed at a high enough level and this in turn leads to incorrect expression 
of downstream NC specifiers such as Sox10 and the synchronicity of 
maintaining multipotency, proliferation and differentiation of neural crest is lost 
(Fig. 6 bottom route). Recently it has been shown that regulation of 
transcriptional elongation to be important for genes regulating cell cycle and 
signal transduction (Williams et al., 2015). c-Myc is an important regulator for 
such processes and as we show here it is clearly important in the regulation of 
the neural crest. 
To conclude, we provide evidence that the P-TEFb activation of 
transcriptional elongation is an important step regulating the correct expression 
of neural crest genes and that this is mediated through the action of c-Myc. It is 
possible that a polymerase pausing step is acting to prime c-Myc for 
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transcription to ensure the correct temporal expression of NC genes and 
therefore a synchronous development of this cell type into its derivatives. 
Polymerase pausing has previously been shown to be important in cells, which 
undergo synchronous gene expression and development. Compared to 
stochastic uncoordinated gene expression in the whole embryo, the 
development of the NC requires such synchronous gene expression (Boettiger 
and Levine, 2009). c-Myc has been shown here to be particularly sensitive to 
inhibition of transcriptional elongation and so it is possible that c-Myc is a 
paused gene in prospective NC cells (Bai et al., 2010). There has been much 
debate in recent literature as to whether this phenomenon of RNA polymerase 
pausing and regulation of transcriptional elongation is (1) common to all genes 
and (2) whether it might be specific to certain cell types (Luo et al., 2012b). Our 
data contributes to this debate by providing evidence that regulation of 
transcriptional elongation is focussed on c-Myc and is particularly important in 
developing neural crest.  
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Materials and Methods 
 
Embryos, capped RNA synthesis, morpholinos, microinjection and animal 
capping 
All experiments were performed in compliance with the relevant laws 
and institutional guidelines at the University of East Anglia. The research has 
been approved by the local ethical review committee according to UK Home 
Office regulations. Xenopus laevis embryos were obtained as previously 
described (Harrison et al., 2004). Embryos were staged using the Nieuwkoop 
and Faber normal table of Xenopus development (Nieuwkoop, 1994). Full 
length cDNAs for Xenopus laevis CDK9.S (IMAGE:5156812) and CyclinT1 
(IMAGE:7207389) were obtained from the IMAGE Clone collection. CDK9.L 
was obtained from Dr Paul Mead. The cDNA clones were all completely 
sequenced before subcloning into relevant vectors. Capped RNA was 
synthesised using the SP6 mMESSAGE mMACHINETM (Ambion) kit for Wnt1, 
Noggin, c-Myc (from Carole Labonne), LacZ and mutagenesis rescue 
constructs for CDK9.S, CDK9.L and CyclinT1. Mutagenesis was carried out 
using the QuickChange II XL Site-Directed Mutagenesis kit (Agilent 
Technologies). Morpholino oligos (MOs) were designed and made by Gene 
Tools. Morpholino sequences are: Standard control (CoMO) 5’-
CCTCTTACCTCAGTTACAATTTATA-3’, CDK9.S 5’-
ATGGCCAAGAACTACGACTCGGTGG-3’, CDK9.L 5’-
ATGGTAAAGAACTACGACTCTGTTG-3’and CyclinT1 5’-
GACATCGTACTTTATGGCAACAAAC-3’. These were tested by in vitro 
translation using the TNT® Coupled Reticulocyte Lysate System (Promega) 
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following manufacturers instructions. Capped RNA and morpholinos were co-
injected with 300 pg LacZ. Microinjections were carried out in 3% Ficoll PM400 
(Sigma). Embryos were injected at the 2 cell stage in either 1 or both cells. β-
Galactosidase activity was detected by colorimetric reaction using Red-Gal 
(Sigma). Embryos were staged and ﬁxed for 2 hours at room temperature in 
MEMFA. Animal capping was carried out as previously described (Garcia-
Morales et al., 2009).  
Wholemount in situ hybridisation  
Single and double in situ hybridisation was carried out as previously 
described (Harrison et al., 2004). Probes were synthesised for c-Myc 
(IMAGE:4884683), Sox10, Zic1, Zic3, Pax3, Sox2, Slug/Snail2, FoxD3, Sox9, 
CDK9.S, CDK9.L and CyclinT1.  
Cryosectioning 
Embryos were fixed in MEMFA for 1 hour, washed twice for 5 minutes 
in PBST and then put in 30% sucrose for 4 hours at room temperature. Embryos 
were then transferred to cryomoulds filled with optimal cutting temperature 
(OCT) compound and left at 4oC overnight. Embryos were then positioned 
appropriately for sectioning and left at -20oC overnight. Embryos were 
sectioned using the LEICA CM 1950 Cryostat and sections were placed on 5% 
TESPA slides. Slides were then washed for 5 minutes in PBST and covered 
with a coverslip using hydromount. Images were taken using a Zeiss CCD 
upright microscope with colour camera. 
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Alcian blue staining 
Embryos were fixed for 1 hour at room temperature, dehydrated with 5 
washes of 100% ethanol (EtoH) for 5 minutes each at RT and then left in Alcian 
blue staining solution for 3 nights. After this they were washed 3 times for 15 
minutes in 95% ethanol at RT then rehydrated in 2% KOH. This was done 
gradually using 10 minute washes of 75% EtoH in 2% KOH, 50% EtoH in 2% 
KOH, 25% EtoH in 2% KOH then 3 2% KOH washes. Embryos were then 
stored in glycerol to make embryos more transparent. Facial cartilage was then 
dissected out before imaging. 
RNA extraction, PCR, Q-PCR and RNA sequencing 
For the PCR, Q-PCR and RNA-sequencing experiments animal caps 
were cut at stage 8 and allowed to develop to stage 15. Approximately 200 caps 
were required for each condition tested to generate enough RNA for 
sequencing. Caps were collected in batches of approx. 30 and RNA purified. 
Each batch was tested by RT_PCR or QPCR to make sure the caps were 
expressing the relevant NC, neural or ectodermal markers. Total RNA was 
extracted using TRIzol® (15596-026, Life technologies, UK) and DNAse treated. 
Reverse transcription was performed using SuperScript® II reverse 
transcriptase (18064-014, Invitrogen, CA, USA), with 1 μg total RNA and 
random primers (C1181, Promega, Southampton, UK). Brightwhite 96 well 
plates (BW-FAST) and high quality optical plate seals (BW-ADVSEAL) were 
used (PrimerDesign Ltd, Southampton, UK). Gene-specific nucleotide 
sequences were detected using Precision™ FAST-LR 2x mastermix 
(PrimerDesign Ltd, Southampton, UK). Quantitative RT-PCR was performed in 
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a final volume of 20 μL using a 7500 FAST real-time PCR instrument (Roche) 
under the following cycling conditions: 95°C for 20 s, 40 cycles at 95°C for 3 s, 
60°C for 30 s.  After cycling, a melting curve was recorded between 60°C and 
95°C under the following 95°C for 15 s, 60°C for 1 min, 95°C for 15 s, 60°C for 
15 s with a ramp rate of 0.11°C s-1. Detection primers were designed using 
Primer3 software (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) 
and custom designed by PrimerDesign Ltd, UK where indicated (Rozen and 
Skaletsky, 2000). Their oligonucleotide sequences are provided in 
supplementary table 1. In-house designed primers were synthesized by 
eurofins (Norwich, UK) and custom primers were designed by and purchased 
from PrimerDesign Ltd (PrimerDesign Ltd, Southampton, UK).  
For the RNA seq experiments to determine whether we get a similar loss 
of neural crest specifying genes compared to the whole embryo data, the 
animal cap samples were initially tested by in situ hybridisation and RT-PCR. 
RNA sequencing was carried out to investigate which genes were affected by 
leflunomide across the whole genome in the three sample types. 
For RNA sequencing total RNA was fragmented before undergoing cDNA 
library preparation. cDNA was end-repaired, A-tailed and adapter-ligated 
before amplification and size selection. The prepared libraries undergo quality 
control by running on a gel and using a bioanalyser to check library fragment 
size distribution before 100bp paired end sequencing over one lane of a flow 
cell. Samples were multiplexed 2 x 3 and ran on one lane each to yield 
approximately 25 million paired reads per sample. Reads were aligned to the 
Xenopus laevis transcriptome (xlaevisMRNA.fasta) downloaded from Xenbase 
(release 28/09/12) (Bowes et al., 2008; Langmead and Salzberg, 2012). 
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Mapping was carried out with bowtie2 on paired-end samples using default 
parameters. A custom Perl script was used to parse the bowtie results and 
count the number of sequences in each sample mapping to every mRNA 
sequence in the transcriptome file. The table of raw abundances for each 
mRNA was then read into R and differential expression between untreated and 
leflunomide treated samples was calculated using the DEseq package (Anders 
and Huber, 2010). Any transcript with a p-value of <= 0.05 was classed as being 
differentially expressed between untreated and leflunomide treated samples.  
 The data for quantitative RT-PCR experiments were analysed using the 
7500FAST software. Measured Ct values for quantitative RT-PCR technical 
and biological replicates for each gene of interest were analysed using the 
NORMA-gene algorithm (Heckmann et al., 2011). NORMA-gene reduces 
systematic and artificial between-replicate bias utilising the entire data-set of 
the target genes being studied. NORMA-gene is applicable to small data sets 
greater than five genes of interest and is used as our primary analysis tool as it 
produces equal or better normalization compared to the delta-delta ct method. 
Leflunomide affects gene transcription thus impacting upon metabolic and 
neural crest pathways. Therefore, using reference vs. target normalisation is 
not appropriate to measure gene expression.  
 
ChIP-sequencing 
Morpholinos were injected at 2 cell stage embryos and incubated at 26oC in 
0.05x Marc's Modified Ringer's (MMR). Approximately 50 embryos per sample 
were fixed at stage 16 in 1% formaldehyde for 30min. Samples were then 
washed in 125mM glycine solution 30 minutes and then transfer gradually to 
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0.1X MMR. Embryos were homogenized in sonication buffer (20mM TrisHCl 
pH=8, 70mM KCl, 1mM EDTA, 10% glycerol, 5mM DTT, 0.125% NP40, 
protease inhibitors (Roche #04693132001) and stored at -80C. ChIP was 
prepared as previously described (Jallow et al., 2004). After sonication, 
chromatin samples were incubated with RNA Pol II antibody (diagenode 
C15200004) 1ug per 15 embryo equivalent in IP buffer overnight (50mM 
TrisHCl pH=8, 100mM NaCl, 2mM EDTA, 1%NP40, 1mM DTT and protease 
inhibitors) followed by incubation with Dynabeads Protein G for 1h. Beads 
where subsequently washed in ChIP 1 buffer (IP buffer + 0.1% deoxycholate), 
ChIP 2 buffer (ChIP 1 buffer + 400mM NaCl), ChIP 3 buffer (ChIP 1 buffer + 
250mM LiCl) and TE buffer. Material was digested with proteinase K and DNA 
was purified using a QIAGEN kit. Q-PCR was performed pre and post library 
preparation for quality checking and DNA libraries were prepared using Kapa 
Hyper Prep kit (Kapa Biosysistem). Sequencing was done on the Illumina 
HiSeq2000 platform and reads were mapped to the reference X. tropicalis 
genome JGI7.1 using BWA allowing one mismatch. 
 
Small molecule compound treatment 
The small molecule compound leflunomide (Sigma) was dissolved in 
DMSO to make a 10 mM stock. This was then diluted directly into the embryos 
media 0.1xMMR. DMSO was added to the media as a control (Tomlinson et al., 
2012). 
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Figure Legends 
 
Figure 1: The expression of the P-TEFb complex components during 
Xenopus laevis development. Transcripts for the P-TEFb components were 
detected using NBT/BCIP and expression of CDK9.S, CDK9.L and CyclinT1 
appeared blue in the sectioned neurula stage embryo. Sox10 was detected 
using fast red and fluorescence microscopy. (A) CDK9.S expression at stage 
16 and 18 in the neural plate and neural plate border and expression at stages 
26 and 32 in the branchial arches. Scale bar = 100 μm (Bi) 10x magnification 
section of a stage 16 embryo showing CDK9.S expression in the neural plate 
and neural plate border (blue) and Sox10 expression in the neural crest (red). 
(ii) 20x magnification section shows overlap of the blue CDK9.S expression with 
the red Sox10 expression. Expression of CDK9.S is outlined with a dashed 
white line and overlaid onto the Sox10 expression image. Scale bar = 100 μm 
(C) CDK9.L expression at stage 16 and 18 in the neural plate and neural plate 
border and expression at stages 26 and 32 in the branchial arches. Scale bar 
= 100 μm (Di) 10x magnification section of a stage 16 embryo showing CDK9.L 
expression in the neural plate and neural plate border (ii) 20x magnification 
section shows overlap of the blue CDK9.L expression with the red Sox10 
expression. Expression of CDK9.L is outlined with a dashed white line and 
overlaid onto the Sox10 expression image. Scale bar = 100 μm (E) CyclinT1 
expression at stage 15 and 18 in the neural plate and neural plate border and 
expression at stages 26 and 32 in the branchial arches. Scale bar = 100 μm 
(Fi) 10x magnification section of a stage 15 embryo showing CDK9.S 
expression in the neural plate and neural plate border (blue) and Sox10 
expression in the neural crest (red). (ii) 20x magnification section shows overlap 
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of the blue CDK9.S expression with the red Sox10 expression. Expression of 
CDK9.S is outlined with a dashed white line and overlaid onto the Sox10 
expression image. Scale bar = 100 μm. Npb = Neural plate border, ba = 
branchial arches.  
 
Figure 2: Leflunomide treatment affects the development of neural crest 
derivatives expression of neural crest genes. (Ai) Top to bottom shows 
DMSO treated control embryo, 20 μM, 40 μM and 60 μM leflunomide treated 
Xenopus laevis embryos. Leflunomide is applied at stage 15. Scale bar = 
500μm (ii) Top to bottom shows DMSO treated control embryo, 60 μM 
leflunomide applied at stage 1, 8 and 12. Phenotype is observed at stage 38. 
Black arrow heads indicate pigment cell loss. Scale bar = 300μm (Bi) Graph 
showing the percentage of embryos displaying a pigment loss phenotype after 
treatment of DMSO n=155, 20 μM n=158, 40 μM n=164 and 60 μM leflunomide 
n=141. *=P<0.05 by Kruskall Wallis statistical test. (ii) Graph showing the 
percentage of embryos displaying a pigment loss phenotype after treatment of 
DMSO and 60 μM leflunomide applied at stage 1 (DMSO n=60 leflunomide 
n=72), 8  (DMSO n=67 leflunomide n=73) and 12 (DMSO n=63 leflunomide 
n=67). *=P<0.05 by Kruskall Wallis statistical test.  (C) Whole mount in situ 
hybridisation carried out on embryos treated with either DMSO or 60 μM 
leflunomide from stage 4 until stage 13 (Zic1, Zic3 and Pax3) or stage 15 (Sox2). 
The neural plate border markers Zic1, Zic3 and Pax3 show no change in 
expression. Similarly, no change is seen for neural plate marker Sox2. Scale 
bar = 200 μm (D) Whole mount in situ hybridisation carried out on embryos 
treated with either DMSO or 60 μM leflunomide from stage 4 until stage 13 (c-
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Myc) or stage 15 (Sox10, Slug/Snail2 and FoxD3). Specific loss of c-Myc 
expression is seen in the anterior region of the embryo (black arrows) and no 
loss of expression is seen in the posterior neural tissue. Loss of Sox10 
expression can be seen (black arrows) and some loss or alteration of 
expression on Slug/Snail2 and FoxD3. Scale bar = 200 μm (E) RNA sequencing 
carried out on animal caps injected with Wnt-8 and noggin and treated with 
DMSO or leflunomide. The change in expression seen in specific genes found 
in the animal cap sample by RNA sequencing is shown. Green = neural crest 
specifying genes, Orange = neuroectoderm genes, Blue = neural plate border 
specifiers, Grey = heat shock protein. The complete list of genes affected can 
be seen in Supplementary data 1. 
 
Figure 3: Knockdown of P-TEFb components leads to loss of expression 
of neural crest specifying genes. (A) All embryos were injected with 100 ng 
standard control morpholino, 100 ng CDK9.S morpholino and 60ng CYCLINT1 
morpholino in both cells of a two cell stage embryo and fixed at stage 38. Loss 
of melanocytes in the tail head and lateral stripe are indicated by black arrow 
heads. (B) All embryos were injected in one cell of a two cell stage embryo with 
either a control morpholino CoMo, 100 ng CDK9.S morpholino or 60 ng 
CYCLINT1 morpholino. 300 pg of Lac-Z cRNA was co-injected with 
morpholinos and β-gal activity was detected using a red gal stain to monitor 
lineage tracing. in situ hybridisation was then carried out on these embryos for 
neural crest specifying, neural plate border and neural plate genes. c-Myc 
(stage 13) shows tissue specific loss of expression (black arrows). Sox10 
(stage 15) shows loss of expression (black arrows). Slug/Snail2 expression 
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(stage 15) and FoxD3 expression (stage 15) appear partially lost or altered. 
Zic1 expression (stage 12), Zic3 expression (stage 12), Pax3 expression (stage 
12) and Sox2 expression (stage 15) appear unchanged. Quantification of these 
results can be found in Fig. S5D. Scale bar = 200 μm. (C) Knockdown of P-
TEFb components leads to a loss of trigeminal placode markers. All embryos 
were injected in one cell of a two cell stage embryo with either 100 ng control 
morpholino (CoMo), 100 ng CDK9.S morpholino or 60 ng CYCLINT1 
morpholino. 300 pg of Lac-Z cRNA was co-injected with morpholinos and β-gal 
activity was detected using a red gal stain to monitor lineage tracing. in situ 
hybridisation was then carried out on these embryos for trigeminal placode 
markers. Tbx2 expression (stage 18) shows loss of expression specifically in 
the trigeminal placode region (black arrow). Expression in the otic placode and 
dorsal root ganglia in not altered. NeuroD expression (stage 18) shows specific 
loss of expression in the trigeminal placode region (black arrow). ElrD 
expression (stage 18) is lost specifically in the trigeminal placode region (black 
arrow). Expression in the dorsal root ganglia remains unaltered.  
  
Figure 4: c-Myc is a paused gene and CDK9 MO causes c-Myc to become 
more paused during development.       
 (A) Histone methylation and RNA polymerase II (RNAPII) binding at the c-Myc 
gene. Profiles of H3K4me3 (marking active promoters and 5’ ends of gene 
bodies, green), H3K36me3 (showing active transcription, light green) and RNA 
Pol II (RNAPII, purple) (Hontelez et al., 2015) are visualised using the UCSC 
Genome Browser for the c-Myc gene on scaffold_6:7,844,903-7,863,621 (X. 
tropicalis genome assembly version 7.1). The transcriptional profile shows c-
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Myc to be a paused gene in Xenopus blastula and gastrula-stage embryos. 
RNA Pol II profile of the c-Myc gene at stage 16 from embryos injected with 
control MO or Cdk9s MO (blue). Note that the c-Myc gene is proportionately 
more paused in the cdk9 MO treated embryos. 
(B) RNA Pol II ChiP-seq on whole embryos injected with Control MO or Cdk9.S 
MO. i) Histogram plots showing the distribution of the Pausing Index values 
(RPKM TSS +/- 150bp divided by the RPKM on the gene body) in log2 space 
for Control MO-injected (grey) and Cdk9.S MO-injected embryos (orange). The 
populations were shown to be significantly different from each other (Mann-
Whitney P-value<2.2x10-16), indicative of RNAPII redistribution. ii) c-Myc is 
more highly paused in Cdk9 MO treated embryos. Scatter plots of RPKM on 
the gene body versus the transcriptional start site (tss) in Control MO (left panel) 
and  Cdk9.S MO-injected embryos (right panel). The loss of Cdk9 causes an 
increase in the amount of RNA Pol II bound to the promoter compared to the 
rest of the gene body. The c-Myc gene is shown by the blue spot.  Genes with 
the strongest increase in gene body RNAPII have the lowest increase in PI, 
suggesting that RNAPII stalls either at the promoter or in the gene body. The 
effects of RNAPII inhibition on transcript levels is shown in fig 3B. 
 
  
 
 
Figure 5. c-Myc can rescue the effect of Cdk and CyclinT1 morpholino 
knockdown 
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(A) Embryos were co-injected into one cell of a two cell stage embryo with a 
morpholino and c-Myc RNA. 300 pg of Lac-Z cRNA was co-injected with 
morpholinos and RNA. β-gal activity was detected using a red gal stain to 
monitor lineage tracing. Embryos then underwent Sox10 in situ. Injection of 100 
ng Cdk9.S morpholino and 60 ng CyclinT1 morpholino results in a loss of Sox10 
expression on the injected side. Co-injection of Cdk9.S and CyclinT1 
morpholino with 100 pg c-Myc RNA results in a partial rescue of Sox10 
expression. Co-injection of Cdk9.S and CyclinT1 morpholino with 500pg c-Myc 
RNA results in a greater rescue of Sox10 expression. Scale bar = 200 μm. 
These results are quantified in Fig. S6D. (B) Graph showing the percentage of 
embryos displaying an expansion, wild type, partial loss or loss of Sox10 
expression pattern by in situ hybridisation after injection of Cdk9.S morpholino 
alone (n=51) and co-injected with 100 pg (n=114) and 500 pg of c-Myc RNA 
(n=61). CyclinT1 morpholino alone (n=46) and co-injected with 100 pg (n=61) 
and 500 pg of c-Myc RNA (n=52). 500 pg of c-Myc RNA alone (n=34) and 
100ng of a standard control morpholino alone (n=33). 
 
Figure 6: Model displaying the mechanism by which c-Myc is paused in 
neural crest cells. On the left c-Myc is shown in a paused state with Pol ll 
bound to NELF, DSIF and Gdown1. We have shown that a knockdown of the 
P-TEFb components CDK9 and CYCLINT1 leads to a loss of c-Myc expression 
and a subsequent loss of Sox10 expression and incorrect development of 
neural crest derivatives (bottom scenario). This suggests in a wild type neural 
crest cell, P-TEFb is promoting transcriptional elongation of c-Myc. P-TEFb in 
its active form bound to the SEC will phosphorylate DSIF, NELF, Gdown1 and 
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serine2 of the C terminal of RNA Pol ll. This promotes pause release on the c-
Myc gene and allows the subsequent expression of Sox10 leading to correct 
synchronous development of neural crest derivatives (top scenario). S2 = 
Serine2, S5 = Serine5, P = phosphorylation mark, NELF = Negative elongation 
factor, DSIF = DRB sensitivity inducing factor, Pol ll = RNA polymerase II, CDK9 
= Cyclin dependent kinase 9, SEC = Super elongation complex.  
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